By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Atox Bio 

Hi-Tech Park, Edmond J. Safra Campus
Givat-Ram, P.O. Box 39135
Jerusalem    91390  Israel
Phone: n/a Fax: 972-2-658-6689


SEARCH JOBS


Industry
Biotechnology






Company News
Atox Bio Announces Independent Safety Monitoring Committee Recommendation To Continue Phase 3 Study Of AB103 In Necrotizing Soft Tissue Infections 11/3/2016 8:31:41 AM
Atox Bio Awarded Next Milestone-Based Option By BARDA To Support Development Of AB103 For Necrotizing Soft Tissue Infections 6/16/2016 9:39:10 AM
Atox Bio Awarded Next Milestone-Based Option By BARDA To Support Development Of AB103 For Necrotizing Soft Tissue Infections 6/15/2016 1:51:18 PM
Atox Bio Enrolls First Patient In Phase III Study Of Potential Treatment For Necrotizing Soft Tissue Infection (Flesh Eating Bacteria) 12/7/2015 7:44:30 AM
Atox Bio Announces Oral Presentation At The 35th Annual Meeting Of The Surgical Infection Society 4/16/2015 1:06:51 PM
Atox Bio Announces Appointment Of Biotech Veteran Daniel D. Burgess As Chairman Of The Board 12/15/2014 8:39:11 AM
Atox Bio Awarded Contract Worth Up To $24 Million For The Development Of AB103 By The Biomedical Advanced Research and Development Authority (BARDA) 9/29/2014 7:10:21 AM
Atox Bio Release: AB103 Granted Orphan Medicinal Product Designation In The European Union For The Treatment Of Necrotizing Soft Tissue Infections (NSTI) 8/5/2014 7:15:54 AM
Atox Bio Locks In $23 Million 7/24/2014 6:11:02 AM
Atox Bio Reports Positive Tissue Infection Trial Results 11/20/2012 7:34:19 AM
12
//-->